Economic Cost of Age-Related Macular Degeneration: A Review of Recent Research

Author： Ke Kathleen M.  

Publisher： Adis International

ISSN： 1170-229X

Source： Drugs & Aging, Vol.23, Iss.3, 2006-01, pp. : 217-225

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Age-Related Macular Degeneration: Cost-of-Illness Issues

By O'Neill C.  

Drugs & Aging, Vol. 18, Iss. 4, 2001-04 ,pp. : 233-241

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK

By Wolowacz Sorrel E.  

PharmacoEconomics, Vol. 25, Iss. 10, 2007-01 ,pp. : 863-879

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration

By Mitchell Paul  

PharmacoEconomics, Vol. 29, Iss. 2, 2011-02 ,pp. : 107-131

Adis International

Access to resources Recommend Favorite

Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches

By  

Current Molecular Pharmacology, Vol. 4, Iss. 3, 2011-11 ,pp. : 196-232

Bentham Science Publishers

Access to resources Recommend Favorite

The Burden of Age-Related Macular Degeneration

By Schmier Jordana K.   Jones Mechelle L.   Halpern Michael T.  

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 319-334

Adis International

Access to resources Recommend Favorite